Uveitis Clinical Trials Report Released, Covering 80+ Countries
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Clinical Trial Overview: The 2025 'Global Clinical Trials Review on Uveitis' report provides data from over 80 countries, detailing trial numbers, average enrollment, and trial status, aiding pharmaceutical companies in formulating effective market strategies.
- Market Opportunity Analysis: The report highlights that Vyome's data on topical VT-1908 for uveitis indicates its effectiveness, potentially opening a $3 billion market opportunity, attracting increased investor interest.
- Trial Trend Insights: The report analyzes enrollment trends over the past five years and provides the latest clinical trial news, helping companies identify key business opportunities and investment directions to optimize resource allocation.
- Key Participating Companies: The report lists major companies involved in uveitis therapeutics, including Novartis and AbbVie, providing detailed information on each company's related trials, enhancing competitive analysis within the industry.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 248.67 USD with a low forecast of 204.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
15 Buy
9 Hold
0 Sell
Moderate Buy
Current: 221.890
Low
204.00
Averages
248.67
High
289.00
Current: 221.890
Low
204.00
Averages
248.67
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
